MindWalk Holdings Corp.
NASDAQ:HYFTBiotechnology
+$0.01 today
- Market cap
- $50.88M
- Beta
- 0.82
- P/E (TTM)
- -8.1
- EPS (TTM)
- -$0.26
Volume 0.20M
Average 0.32M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
MindWalk Holdings Corp.
NASDAQ:HYFT
Intrinsic Alpha fair value
Locked
Current Price
$1.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +8.2% | +9.4% (6yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +8.2% over three years. Forward estimates point to Revenue at +9.4% (6yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
CAMP4 Therapeutics Corporation NASDAQ:CAMP | $248.50M | $3.96 | Not rated | -2.8 | +13.96% |
ALX Oncology Holdings Inc. NASDAQ:ALXO | $168.70M | $1.22 | Not rated | -0.9 | -25.00% |
Unicycive Therapeutics, Inc. NASDAQ:UNCY | $102.45M | $3.74 | Not rated | -40.8 | -33.02% |
Fortress Biotech, Inc. NASDAQ:FBIO | $64.03M | $1.92 | Undervalued | 0.7 | -30.04% |
Clene Inc. NASDAQ:CLNN | $54.44M | $3.83 | Not rated | -2.1 | -60.05% |
BeyondSpring Inc. NASDAQ:BYSI | $26.47M | $0.64 | Not rated | -8.7 | -28.16% |
Fractyl Health, Inc. Common Stock NASDAQ:GUTS | $12.95M | $0.98 | Not rated | -0.6 | +222.48% |
aTyr Pharma, Inc. NASDAQ:ATYR | $12.11M | $4.94 | Not rated | -0.7 | -18.38% |
Continue the stock analysis
Jump to another research area for this company.